Daito's Facts and Figures
- Top
- Company Profile
- Company Profile
- Daito's Facts and Figures
Net Sales (Consolidated)
468
hundred million yen (46.8 billion yen)
(Consolidated sales for the fiscal year ended May 2024)
The Daito Group’s net sales have amounted to 46.8 billion yen.
Since the Company was listed on the Tokyo Stock Exchange in 2010, its net sales have continued to increase for practically 14 consecutive fiscal years, reaching an amount more than 2 times higher than the net sales at the time of listing.
- The "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29) will be adopted from the fiscal year ended May 31, 2022. A comparison with estimates based on the application of the standard for the prior years before the standard's adoption will be used to determine the amount of revenue recognized.
Percentages of Sales from the Active Pharmaceutical Ingredients (API) Business and the Formulation Product Business
API business : 46 %
Pharmaceutical product business : 53 %
The Company operates with a good balance between its two major businesses.
Its engagement in both the API business and the Pharmaceutical product business enables the Company to ensure information sharing between the two businesses and to provide high-quality products at a low cost through the integrated process of manufacturing both APIs and Pharmaceutical products. The synergy between the two businesses is one of Daito’s strengths.
Annual Number of Tablets Daito Produces
Approx.
32
hundred million (3.2 billion)
(Actual figures for the fiscal year ended May 2024)
Daito produces approximately 3.2 billion tablets a year.
This figure is equivalent to 26 tablets a year for everyone living in Japan.
If you are on medication, it is likely that you have taken a drug produced by Daito.
(In addition to tablets, Daito also produces granules and other forms of drugs.)
Reduction in Japan’s National Medical Expenditure, Achieved through Daito’s Provision of Generic Drugs
552
hundred million yen (46.8 billion yen)
(Based on shipment volume for the fiscal year ending May 2023)
Generic drugs which Daito concentrates on are released after the original drug's patent expires, so their development costs are low, and their drug prices are less than 40% to 50% of the original drug.
The medical cost reduction effect of replacing Daito's generic drug with the original drug was approximately 55.2 billion yen.
Number of Master Files (MFs) Registered
103
(As of May 2023. Including the number of registrations of subsidiaries and group companies.)
The number of officially registered MFs of a pharmaceutical manufacturer almost equals the number of API products it manufactures. A total of 103 MFs are officially registered for Daito Group products, the largest number in Japan.
An MF is a kind of component part of an application for approval for a drug. The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices provides that the MF for an API shall indicate its manufacturing method, specifications, etc.
If an API manufacturer intends to sell an API to another company, the manufacturer will usually register an MF for the API.
Therefore, the number of officially registered MFs of a company is an indicator of the number of API products the company manufactures.
Year of Founding
1942
Daitoa Pharmaceutical Trade Control Company,* the predecessor of Daito, was founded as a control company in charge of the export of Toyama-made home medicines to Southeast Asia.
Daito will celebrate the 80th anniversary of its founding in June 2022.
- In 1991, the Company adopted its current name: Daito Pharmaceutical Co., Ltd.
Number of Employees (Consolidated)
1,108
(Consolidated, as of May 31, 2024, including temporary employees)
In the Daito Group, diverse talents demonstrate their capabilities fully, irrespective of their gender, nationality or age.
The Company has continued to grow since its listing on the Tokyo Stock Exchange, and it has employed many mid-career people.
Number of Staff Members of the Quality and Regulatory Affairs Division
214
(As of June 1, 2024, non-consolidated, including temporary employees)
As a company seriously committed to enhancing the quality of its pharmaceutical products, Daito has 214 staff members working in the Quality and Regulatory Affairs Department, including the Quality Assurance Division and the Quality Control Division.
The Quality and Regulatory Affairs Department staff account for about 24% of Daito’s total workforce.
Number of Detailers
0
Since Daito concentrates its management resources on the manufacture of APIs and Pharmaceutical products, it outsources marketing activities targeting pharmacies and medical institutions to other companies.
Therefore, the Company has no detailers (MRs), who would be in charge of pharmaceutical detailing and sale to medical institutions.